Zogenix has manufactured and shipped over 2,000,000 commercial DosePro units. DosePro needle-free delivery system is currently being co-marketed with Battelle, the world's largest independent research and development organization, to potential biopharmaceutical and government clients. The companies have embarked on a "Less is More" campaign that aims to showcase the simplicity and benefits of the DosePro technology and its ability to provide instantaneous, needle-free, subcutaneous drug delivery.
For more information on the DosePro needle-free delivery system, please visit www.DosePro.com .
About the 2 nd Annual Drug Repositioning Conference
Presenters and panelists will share with the audience best practices, new technologies, case studies, and regulatory developments in drug repositioning and indications discovery. It will feature a variety of speakers from academia, industry, non-profits and government. Their perspectives will provide insight into the field of drug repositioning and the challenges and successes in getting a repositioned drug to the marketplace. Building on last year's conference, the 2 nd Annual Drug Repositioning Conference will discuss what has changed in the last year and what continues to drive interest in drug repositioning. Case studies will give attendees concrete examples of successfully repositioned drugs and there will be a focus on the best pathway to success for repositioning drugs.About SUMAVEL DosePro SUMAVEL DosePro (sumatriptan injection) is indicated for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache episodes. SUMAVEL DosePro should only be used where a clear diagnosis of migraine or cluster headache has been established. SUMAVEL DosePro is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine and should not be administered intravenously. For a given attack, if a patient does not respond to the first dose of SUMAVEL DosePro, the diagnosis of migraine or cluster headache should be reconsidered before administration of a second dose.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts